Key result
Prasugrel reduces major cardiovascular events ~18% vs clopidogrel in patients with ACS.
Why the study?
Does prasugrel reduce thrombotic complications compared to clopidogrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention?
Does prasugrel reduce thrombotic complications compared to clopidogrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention?
Prasugrel is more effective than clopidogrel at reducing thrombotic complications in ACS patients undergoing PCI, but it carries a higher risk of bleeding.
Answers are grounded in this paper and cite their sources.
May support prasugrel over clopidogrel in ACS-PCI; leaves open net benefit and bleeding management in contemporary practice.
Prasugrel (Effient) has been approved for reducing the risk of thrombotic complications in patients with acute coronary syndromes who are to undergo percutaneous coronary intervention. In a large clinical trial (N Engl J Med 2007; 357:2001-2005), prasugrel was superior to clopidogrel (Plavix), another drug of its class, in this situation. However, bleeding complications were more frequent with prasugrel, and so this drug should be avoided in patients at higher risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Lazar et al. (2009) conducted a review in Acute coronary syndromes (n=13,608). Prasugrel vs. Clopidogrel (300-mg loading dose, then 75 mg daily) was evaluated on Composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke (p=<0.001). Prasugrel reduced the composite of cardiovascular death, nonfatal MI, or nonfatal stroke compared to clopidogrel in patients with acute coronary syndromes.
Synapse has enriched 10 related papers. Consider them for comparative context: